RE:RE:RE:GSK drops the development of engineered cell therapy October 27, 2022 - Bluebird spinout 2seventybio and China-based CAR-T company JW Therapeutics collaborate to build out a cell therapy platform with the aim of developing T cell receptor (TCR) therapies for solid tumors. 2seventy bio secured its legacy in the cell therapy arena by developing FDA-approved CAR-T Abecma with Bristol Myers. Meanwhile, JW Therapeutics has achieved cell therapy success in China, where its relma-cel became the second CAR-T to secure regulatory approval.
Other biotechs have had their eyes on MAGE-A4, a type of cancer-testis antigen expressed in many solid tumors. Earlier this week, Adaptimmune restated that its MAGE-A4 franchise remains its lead program, as the company scooped other TCR programs from GSK.
https://www.fiercebiotech.com/biotech/bluebird-spinout-2seventybio-jw-therapeutics-ink-3m-licensing-deal-solid-tumor-cell-therapy